AR105669A1 - IMPROVED RECOMBINANT FACTOR VII - Google Patents
IMPROVED RECOMBINANT FACTOR VIIInfo
- Publication number
- AR105669A1 AR105669A1 ARP160102459A ARP160102459A AR105669A1 AR 105669 A1 AR105669 A1 AR 105669A1 AR P160102459 A ARP160102459 A AR P160102459A AR P160102459 A ARP160102459 A AR P160102459A AR 105669 A1 AR105669 A1 AR 105669A1
- Authority
- AR
- Argentina
- Prior art keywords
- factor vii
- preparation
- recombinant factor
- hemorrhages
- hemophilia
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Reivindicación 1: Una preparación de un factor VII recombinante caracterizada porque el factor VII recombinante en la preparación presenta un patrón de glicosilación en sus sitios de N-glicosilación con las siguientes características: (i) una cantidad relativa de glicanos que comprenden N-acetilglucosamina bisectada (bisG1cNAc) que representa al menos 10% de la cantidad total de glicanos unidos a los sitios de N-glicosilación del factor VII en la preparación. Reivindicación 10: La preparación del factor VII recombinante de acuerdo con cualquiera de las reivindicaciones 1 a 9, caracterizada porque el factor VII recombinante en la preparación presenta una cantidad media de al menos 9 residuos de acido glutámico g-carboxilados. Reivindicación 12: La preparación del factor VII recombinante de acuerdo con cualquiera de las reivindicaciones 1 a 11, caracterizada porque el factor VII recombinante en la preparación presenta una o más de las siguientes características: (a) es el factor recombinante VII humano; (b) es un factor VII activado; (c) es una proteína de fusión que comprende un factor VII de cadena simple no activado fusionado con un componente de fusión o la cadena liviana y/o la cadena pesada del factor VIIa activado fusionadas con componentes de fusión separados; (d) comprende uno o más agentes adicionales conjugados con sus una o mas cadenas polipeptídicas; y/o (e) es producida por células humanas o por una línea de células humanas. Reivindicación 14: Una composición farmacéutica caracterizada porque comprende una preparación de un factor VII recombinante de acuerdo con cualquiera de las reivindicaciones 1 a 13. Reivindicación 16: La preparación del factor VII recombinante o la composición farmacéutica de acuerdo con la reivindicación 15, caracterizadas porque pueden ser usadas en el tratamiento de los trastornos de la coagulación, donde los trastornos de la coagulación se seleccionan del grupo que consiste en la hemofilia A, la hemofilia B, la hemofilia adquirida, la deficiencia congénita del factor VII, la profilaxis de la hemofilia en aquellos pacientes que están siendo tratados con inhibidores, los traumas, las hemorragias en los casos de emergencia o en las intervenciones quirúrgicas, por ejemplo, en las cirugías en la columna o en el corazón, la enfermedad de Glanzmann, las lesiones provocadas por el estallido de los pulmones o las hemorragias en general, tales como las hemorragias intracerebrales, las hemorragias inespecíficas o las hemorragias alveolares difusas.Claim 1: A preparation of a recombinant factor VII characterized in that the recombinant factor VII in the preparation has a glycosylation pattern at its N-glycosylation sites with the following characteristics: (i) a relative amount of glycans comprising bisected N-acetylglucosamine (bisG1cNAc) which represents at least 10% of the total amount of glycans bound to the N-glycosylation sites of factor VII in the preparation. Claim 10: The preparation of the recombinant factor VII according to any one of claims 1 to 9, characterized in that the recombinant factor VII in the preparation has an average amount of at least 9 g-carboxylated glutamic acid residues. Claim 12: The preparation of the recombinant factor VII according to any one of claims 1 to 11, characterized in that the recombinant factor VII in the preparation has one or more of the following characteristics: (a) it is the human recombinant factor VII; (b) is an activated factor VII; (c) is a fusion protein comprising a single chain factor VII not activated fused with a fusion component or light chain and / or heavy chain activated factor VIIa fused with separate fusion components; (d) comprises one or more additional agents conjugated with their one or more polypeptide chains; and / or (e) is produced by human cells or by a human cell line. Claim 14: A pharmaceutical composition characterized in that it comprises a preparation of a recombinant factor VII according to any one of claims 1 to 13. Claim 16: The preparation of the recombinant factor VII or the pharmaceutical composition according to claim 15, characterized in that they can be used in the treatment of coagulation disorders, where coagulation disorders are selected from the group consisting of hemophilia A, hemophilia B, acquired hemophilia, congenital factor VII deficiency, hemophilia prophylaxis in those patients who are being treated with inhibitors, traumas, hemorrhages in emergencies or surgical interventions, for example, in spinal or heart surgeries, Glanzmann's disease, lesions caused by the outbreak of the lungs or hemorrhages in general, such as intracerebral hemorrhages Rare, nonspecific hemorrhages or diffuse alveolar hemorrhages.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
LU92796 | 2015-08-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR105669A1 true AR105669A1 (en) | 2017-10-25 |
Family
ID=54011849
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP160102459A AR105669A1 (en) | 2015-08-10 | 2016-08-10 | IMPROVED RECOMBINANT FACTOR VII |
Country Status (2)
Country | Link |
---|---|
AR (1) | AR105669A1 (en) |
WO (1) | WO2017025566A1 (en) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60137950D1 (en) * | 2000-10-02 | 2009-04-23 | Novo Nordisk Healthcare Ag | METHOD FOR PRODUCING VITAMIN K-DEPENDENT PROTEINS |
WO2012016576A1 (en) * | 2010-08-04 | 2012-02-09 | Glycotope Gmbh | Improved recombinant human follicle-stimulating hormone |
-
2016
- 2016-08-10 WO PCT/EP2016/069044 patent/WO2017025566A1/en active Application Filing
- 2016-08-10 AR ARP160102459A patent/AR105669A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2017025566A1 (en) | 2017-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
De La Mata | Platelet rich plasma. A new treatment tool for the rheumatologist? | |
BR112019006918A2 (en) | actriib proteins variants and uses thereof | |
CR8131A (en) | NOVELTY PEPTIDES THAT JOIN THE Erythropoietin Receptor | |
Di Liberto et al. | Anxiolytic effects of muscarinic acetylcholine receptors agonist oxotremorine in chronically stressed rats and related changes in BDNF and FGF2 levels in the hippocampus and prefrontal cortex | |
BRPI0515823A (en) | use of omega-3 fatty acid (s) for the treatment of hypercholesterolaemia caused by antiretroviral treatment in HIV-infected patients | |
ECSP11010810A (en) | MONOCLONAL ANTIBODIES AGAINST THE INHIBITOR OF THE TISSULAR FACTOR ROUTE (TFPI) | |
Lei et al. | Activation of cerebral recovery by matrix metalloproteinase-9 after intracerebral hemorrhage | |
CY1124143T1 (en) | BONE MORPHOGENETIC PROTEINS | |
ECSP12012134A (en) | OPTIMIZED MONOCLONAL ANTIBODIES AGAINST THE INHIBITOR OF THE TISSULAR FACTOR ROUTE (TFPI) | |
BR112015022896A2 (en) | high penetration drugs and their compositions for the treatment of parkinson's disease | |
BR112018010160A8 (en) | recombinant human c1 esterase inhibitor and uses thereof | |
UY37611A (en) | FORMULATIONS OF EVOLOCUMAB HIGH CONCENTRATION AND LOW VISCOSITY AND METHODS TO PREPARE THEM | |
BR112017012588A2 (en) | Bicyclic heteroaryl heteroaryl compounds of benzoic acid as retinoic acid beta receptor agonists (rarbeta) | |
WO2018005801A3 (en) | Novel non-systemic tgr5 agonists | |
Lecker et al. | High concentrations of tranexamic acid inhibit ionotropic glutamate receptors | |
BR112023020219A2 (en) | ANTI-IL-2R AGONIST ANTIBODIES AND METHODS OF USE | |
CO2023005057A2 (en) | Compounds and compositions as tlr signaling modulators | |
AR092691A1 (en) | PHARMACEUTICAL COMPOSITION THAT REBAMIPIDA INCLUDES | |
MX2023014327A (en) | 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and medical uses thereof. | |
WO2015048188A3 (en) | Modified fibroblast growth factors for the treatment of ocular disorders | |
EA202092305A1 (en) | CONNECTIONS AS TLR2 ALARM MODULATORS | |
Mehravaran et al. | Evaluation of the relationship between the pattern of midfacial fractures and amaurosis in patients with facial trauma | |
AR083460A1 (en) | HYDROLYZES OF ANIMAL PROTEINS OF MARINE ORIGIN WITH NEUROPROTECTOR PROPERTIES | |
AR105669A1 (en) | IMPROVED RECOMBINANT FACTOR VII | |
Shetty | Effectiveness of intravenous haemocoagulase on haemorrhage control in bi-maxillary orthognathic surgery—a prospective, randomised, controlled, double-blind study |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |